Skip to main content
SpringerLink
Log in

The Clinical Pharmacokinetics of Darifenacin

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Darifenacin hydrobromide is a selective muscarinic M3 receptor antagonist that is indicated for use in treatment of overactive bladder disorder. Darifenacin was found to have a short terminal elimination half-life after intravenous and immediate-release oral dosage forms (3–4 hours) but this increased with a prolonged-release (PR) formulation (14–16 hours). The absolute bioavailability of darifenacin from 7.5 and 15mg PR tablets was estimated to be 15.4% and 18.6%, respectively. With repeated once-daily oral administration of the PR formulation, peak plasma concentrations of darifenacin are achieved approximately 7 hours post-dose. After oral administration, darifenacin is well absorbed from the gastrointestinal tract and very little unchanged drug (<2%) is recovered in the faeces. Steady state is achieved after 6 days of once-daily administration of the PR formulation. As expected, values of peak plasma concentration (Cmax) and area under the plasma concentration-time curve are dose dependent, although the increase in plasma concentrations is proportionally greater than the increase in dose owing to saturation of presystemic metabolism. From intravenous administration, it has been established that darifenacin possesses a moderate-to-high hepatic extraction ratio, with high plasma clearance (36–52 L/h) and a volume of distribution (165–276L) that exceeds total body water. It is highly protein bound (98%), primarily to α1-acid glycoprotein. Darifenacin is subject to extensive hepatic metabolism, with 3% of unchanged drug excreted in urine and faeces. Metabolism is mediated by hepatic cytochrome P450 2D6 and 3A4, the main metabolic routes being monohydroxylation in the dihydrobenzfuran ring, dihydrobenzfuran ring opening, and N-dealkylation of the pyrrolidine nitrogen. Several possibly important drug-drug interactions have been identified with darifenacin, including ketoconazole, erythromycin and fluconazole, each of which increases darifenacin mean Cmax by 9.52-, 2.28- and 1.88-fold, respectively. When given with imipramine, darifenacin causes 1.6-fold higher plasma concentrations of the antidepressant and its major metabolite. Moderate hepatic impairment, but not renal insufficiency, has been shown to increase plasma concentrations of the drug. The pharmacokinetic profile of darifenacin is not affected by food.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Fig. 3
Table II
Table III
Table IV
Fig. 4
Fig. 5
Table V
Table VI
Table VII

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167–78

    Article  PubMed  Google Scholar 

  2. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004; 64: 1643–56

    Article  PubMed  CAS  Google Scholar 

  3. Caulfield MP, Birdsall NJ. International Union of Pharmacology: XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279–90

    PubMed  CAS  Google Scholar 

  4. Andersson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997; 50: 74–84

    Article  PubMed  CAS  Google Scholar 

  5. Chess Williams R, Chappie CR, Yamanishi T, et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001; 21: 243–8

    Article  PubMed  CAS  Google Scholar 

  6. Alabaster VA. Discovery and development of selective M3 antagonists for clinical use. Life Sci 1997; 60: 1053–60

    Article  PubMed  CAS  Google Scholar 

  7. Novartis media releases. Novartis receives European marketing authorization for Emselex® [online]. Available from URL: http://www.novartis.com [Accessed 2005 Feb 27]

  8. Kaye B, Herron WJ, Macrae PV, et al. Rapid, solid phase extraction technique for the high-throughput assay of darifenacin in human plasma. Anal Chem 1996; 68: 1658–60

    Article  PubMed  CAS  Google Scholar 

  9. Beaumont KC, Cussans NJ, Nichols DJ, et al. Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. Xenobiotica 1998; 28: 63–75

    Article  PubMed  CAS  Google Scholar 

  10. Study report DM11. The excretion and metabolism of [14C]-UK-88,525 in man following administration of multiple oral doses of 5mg three times daily to healthy volunteers. East Hanover (NJ): Novartis, 2002 Jan 23. (Data on file)

  11. Study report 137-219. Double blind, placebo controlled, fourway crossover study to investigate the toleration, safety, pharmacokinetics and pharmacodynamics of single escalating doses of intravenous darifenacin in healthy male volunteers. East Hanover (NJ): Novartis, 2001 May 4. (Data on file)

  12. Study report 137-214. An open, randomised, four way crossover pilot study to investigate if site of drug delivery and formulation affects the bioavailability of a single dose of darifenacin. East Hanover (NJ): Novartis, 2002 Mar 21. (Data on file)

  13. Study report JP-95-501. A single blind, placebo controlled, four way crossover, escalating single oral dose study to investigate safety and pharmacokinetics of controlled-release darifenacin and of immediate release darifenacin in healthy male Japanese volunteers. East Hanover (NJ): Novartis, 2002 Sep 23. (Data on file)

  14. Study report 137-218. An open, randomised, four-way crossover study in healthy male volunteers to assess the effect of dose on the pharmacokinetics of darifenacin after controlledrelease matrix tablets (7.5,15 & 30 mg, o.d. for 10 days) and to compare this with immediate release oral capsules (2.5, 5 and 10mg t.i.d. for 10 days). East Hanover (NJ): Novartis, 2002 Mar 27. (Data on file)

  15. Study report JP-95-502. An open, randomised, crossover, single oral dose study to investigate the effect of food on the pharmacokinetics of darifenacin controlled-release tablet in healthy male Japanese volunteers. East Hanover (NJ): Novartis, 2002 Sep 5. (Data on file)

  16. Study report 137-670. The effect of food on the bioavailability of darifenacin controlled-release tablets. East Hanover (NJ): Novartis, 2002 Jan 3. (Data on file)

  17. Nichols DJ. No effects of food on pharmacokinetics of darifenacin in multiple doses [abstract no. 346]. Pharmacol Toxicol 2001; 89 Suppl. 1: 89

    Google Scholar 

  18. Study report 137-226. An open, randomized, two-way crossover, multiple dose study to assess the safety, toleration and pharmacokinetics of darifenacin at steady-state from oral doses (30mg od) of the controlled-release formulation administered to healthy male volunteers in the fed and fasted states. East Hanover (NJ): Novartis, 2000 Jan 18. (Data on file)

  19. Study report A1371015. A randomised, double blind, parallel group placebo controlled study to assess the safety and toleration of multiple oral doses of darifenacin (CR) 60mg once daily. East Hanover (NJ): Novartis, 2002 Feb 8. (Data on file)

  20. Study report 137-221. An open, randomised, three-way crossover study, in healthy male volunteers, to assess the relative and absolute bioavailability of immediate and controlled-release formulations of darifenacin. East Hanover (NJ): Novartis, 2002 Mar 28. (Data on file)

  21. Fuhr U, Staib AH, Harder S, et al. Absorption of ipsapirone along the human gastrointestinal tract. Br J Clin Pharmacol 1994; 38: 83–6

    Article  PubMed  CAS  Google Scholar 

  22. Kerbusch T, Wahlby U, Milligan PA, et al. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 2003; 56: 639–52

    Article  PubMed  CAS  Google Scholar 

  23. Study report DM26. In vitro permeability of UK-88,525 in CaCo-2 cells. East Hanover (NJ): Novartis, 2003 Apr 9. (Data on file)

  24. Varma MV, Sateesh K, Panchagnula R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm 2005; 2(1): 12–21

    Article  PubMed  CAS  Google Scholar 

  25. Brocks DR. Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci 1999; 2: 39–46

    PubMed  CAS  Google Scholar 

  26. Report DM8. Binding of [14C]-UK-88,525 in the plasma of rabbit, rat, dog and man. East Hanover (NJ): Novartis, 2002 Jan 23. (Data on file)

  27. Study report DM8A. Binding of UK-88,525 and UK-148,993 in the plasma of rabbit, rat, dog and man. East Hanover (NJ): Novartis, 2002 Jan 23. (Data on file)

  28. Study report DM8B. Protein binding of [14C]-UK-88,525 to human albumin and α-1-acid glycoprotein. East Hanover (NJ): Novartis, 2002 Feb 21. (Data on file)

  29. Study report DM8C. Binding of UK-88,62 and UK-73,689 in human plasma. East Hanover (NJ): Novartis, 2002 Feb 21. (Data on file)

  30. Devineni D, Skerjanec A, Woodworth TG. Low central nervous system (CNS) penetration by darifenacin, a muscarinic M3 selective receptor antagonist, in rats [abstract]. British Pharmacological Society Summer Meeting; 2005 July 6–8; Cambridge

    Google Scholar 

  31. Study report DM7. Tissue distribution of [14C]-UK-88,525 in male and female rats following administration of a single intravenous (4 mg/kg) dose. East Hanover (NJ): Novartis, 2002 Jan 23. (Data on file)

  32. Kay GG, Abou-Donia MB, Messer WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53: 2195–201

    Article  PubMed  Google Scholar 

  33. Study report DM24. Concentration of [14C]-UK-88,525 in the cerebrospinal fluid of male rats after oral administration (10 mg/kg): relationship to unbound concentration of [14C]-UK-88,525 in plasma. East Hanover (NJ): Novartis, 2002 Jan 23. (Data on file)

  34. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function in the elderly population: effects of darifenacin. J Urol 2004; 173: 493–8

    Article  Google Scholar 

  35. Study report DM1. In vitro metabolism of UK-88,525. East Hanover (NJ): Novartis, 2001 Dec 21. (Data on file)

  36. Study report DM1A. In vitro metabolism of UK-88,525 in human liver microsomes; enzymology of UK-148,993 formation. East Hanover (NJ): Novartis, 2001 Dec 21. (Data on file)

  37. Study report DM1B. In vitro metabolism of UK-88,525 in human liver microsomes; enzymology of UK-88,862 formation. East Hanover (NJ): Novartis, 2001 Dec 21. (Data on file)

  38. Study report DM1D. UK-88,525 in vitro interaction studies with cytochrome P450 inhibitors and substrates. East Hanover (NJ): Novartis, 2002 Jan 23. (Data on file)

  39. Skerjanec A, Devineni D. Affinity of darifenacin for the P-glycoprotein efflux pump: a mechanism contributing to the CNS sparing profile? Newcastle: British Pharmacological Society, University of Newcastle; 2004 Dec 14–16

    Google Scholar 

  40. Study report 137-203. An open, randomised, three way crossover study to compare the pharmacokinetics of darifenacin when given as a solution in the fasted state, capsules in the fasted state and capsules in the fed state. East Hanover (NJ): Novartis, 2001 Sep 4. (Data on file)

  41. Study report phase3. A population pharmacokinetic and pharmacodynamic analysis of darifenacin phase 3 data. East Hanover (NJ): Novartis, 2002 Sept 3. (Data on file)

  42. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815–50

    Article  PubMed  CAS  Google Scholar 

  43. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342–9

    Article  PubMed  CAS  Google Scholar 

  44. NDA21-513, common technical document. Darifenacin summary of clinical pharmacology: module 2.7.2, sections 3.1.2.1 and 3.1.4.4, tables 13 and 23. East Hanover (NJ): Novartis, 2002 Nov 26 (Data on file)

    Google Scholar 

  45. Study report bridging: a population pharmacokinetic bridging analysis of darifenacin. East Hanover (NJ): Novartis. (Data on file)

  46. Devineni D, Skerjanec A, Greig G, et al. Pharmacokinetics of darifenacin, an M3 selective receptor antagonist: effects of renal or hepatic impairment. Proceedings of the British Pharmacological Society [online]. Available from URL: http://www.pa2online.org/Vol2Issue4abst157P.html [Accessed 2006 Feb 27]

  47. Study report A1371005. An open, two period, parallel group study to compare the single and multiple dose pharmacokinetics, safety and toleration of darifenacin patients with chronic stable hepatic disease to healthy subjects with normal hepatic function. East Hanover (NJ): Novartis, 2002 Oct 8. (Data on file)

  48. Study report DM1E. Inhibition of CYP3A4 activity in human liver microsomes by UK-88,525 and metabolites: a comparison with competitor agents. East Hanover (NJ): Novartis, 2002 Jan 23. (Data on file)

  49. Study report DM1C. In vitro inhibition studies of UK-88,525 in human liver microsomes. East Hanover (NJ): Novartis, 2002 Jan 23. (Data on file)

  50. Study report DM1G. Inhibition of CYP2D6 metabolism by UK-88,525: effect of pre-incubation. East Hanover (NJ): Novartis, 2001 Oct 22. (Data on file)

  51. Study report DM1H. Inhibition of CYP2D6 activity in human liver microsomes by UK-73,689, UK88,862 and UK-148,993. East Hanover (NJ): Novartis, 2002 Mar 4. (Data on file)

  52. Study report A1371007. A randomised, placebo controlled, two-period cross-over study to investigate the effects of ketoconazole on the pharmacokinetics, pharmacodynamics, safety and toleration of darifenacin at steady state. East Hanover (NJ). Novartis, 2002 Jan 3. (Data on file)

  53. Devineni D, Skerjanec A, Woodworth TG. Drug-drug interaction potential of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, with cytochrome P450 (CYP)3A4 inhibitors and substrates [abstract]. AAPS J 2005; 7 Suppl. 2: M1302

    Google Scholar 

  54. Study report A1371008. A randomised placebo controlled, parallel group study to investigate the effects of paroxetine on the pharmacokinetics, pharmacodynamics, safety and toleration of darifenacin at steady state. East Hanover (NJ): Novartis, 2001 Dec 20. (Data on file)

  55. Study report A1371010. A randomised, placebo controlled, two-period cross-over study to investigate the effects of cimetidine on the pharmacokinetics, pharmacodynamics, safety and toleration of darifenacin at steady state. East Hanover (NJ): Novartis, 2002 Jan 18. (Data on file)

  56. Study report A1371022. A randomised, placebo controlled, parallel group study to investigate the effects of erythromycin on the pharmacokinetics, pharmacodynamics, safety and toleration of darifenacin at steady state. East Hanover (NJ): Novartis, 2001 Dec 18. (Data on file)

  57. Study report A1371024. A randomised, placebo controlled, two-period cross-over study to investigate the effects of fluconazole on the pharmacokinetics, pharmacodynamics, safety and toleration of darifenacin at steady state. East Hanover (NJ): Novartis, 2001 Nov 19. (Data on file)

  58. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73–8

    Article  PubMed  CAS  Google Scholar 

  59. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262–5

    Article  PubMed  CAS  Google Scholar 

  60. Study report A1371023. An open, randomised, multiple dose, two way crossover, two cohort study to demonstrate the bioequivalence of darifenacin when administered as the proposed commercial 7.5 and 15mg tablets and as the 7.5 and 15mg clinical research tablets in the fasted state. East Hanover (NJ): Novartis, 2001 Nov 16. (Data on file)

  61. Study report A1371038. An open study to investigate the effects of multiple doses of darifenacin 30mg controlled-release tablets on the debrisoquine metabolic ratio of healthy male subjects. East Hanover (NJ). Novartis, 2002 Jul 19. (Data on file)

  62. Study report A1371045. An open, randomised, multiple dose two way crossover study to demonstrate the bioequivalence of darifenacin 15mg controlled-release tablets manufactured at the Brooklyn and Barceloneta sites and to investigate darifenacin’s inhibition of debrisoquine metabolism. East Hanover (NJ): Novartis, 2002 Oct 15. (Data on file)

  63. Study report A1371031. A randomised, double blind, placebo controlled, two period crossover study to investigate the effects of multiple dose darifenacin (CR) on the pharmacokinetics of a single oral dose of oral midazolam. East Hanover (NJ): Novartis, 2002 Jan 21. (Data on file)

  64. Dahl ML, Iselius L, Alm C, et al. Polymorphic 2-hydroxylation of desipramine: a population and family study. Eur J Clin Pharmacol 1993; 44: 445–50

    Article  PubMed  CAS  Google Scholar 

  65. Study report A1371009. A randomised, placebo controlled, two-period cross-over study to investigate the effects of darifenacin on the pharmacokinetics, pharmacodynamics, safety and toleration of imipramine at steady state. East Hanover (NJ): Novartis, 2001 Dec 19. (Data on file)

  66. Study report A1371025. An open, randomized, multiple dose study in healthy adult male volunteers to investigate the dose strength equivalence of the darifenacin proposed commercial controlled-release tablets (7.5 mg, 15 mg, and 30 mg), and to investigate the pharmacokinetics. East Hanover (NJ): Novartis, 2002 Sep 5. (Data on file)

  67. Study report A1371021. A double blind, randomised, placebo controlled, parallel group study to investigate the effect of orally administered darifenacin (cr) on the steady state pharmacokinetics of digoxin in healthy male volunteers. East Hanover (NJ): Novartis, 2002 Feb 8. (Data on file)

  68. Study report A1371030. A double blind, randomised, placebo controlled, two-way crossover study to investigate the effect of orally administered darifenacin (cr) on the pharmacodynamics of warfarin in healthy male volunteers. East Hanover (NJ): Novartis, 2002 Mar 2. (Data on file)

  69. Leucht S, Hackl HJ, Steimer W, et al. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. Psychopharmacology (Berl) 2000; 147: 378–83

    Article  CAS  Google Scholar 

  70. Albers LJ, Reist C, Helmeste D, et al. Paroxetine shifts imipramine metabolism. Psychiatry Res 1996; 59: 189–96

    Article  PubMed  CAS  Google Scholar 

  71. Wallis RM, Napier CM. Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci 1999; 64: 395–401

    Article  PubMed  CAS  Google Scholar 

  72. Chappie CR, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective antagonist, in the treatment of overactive bladder: a pooled analysis of phase III studies. BJU Int 2005; 95: 993–1001

    Article  Google Scholar 

  73. Foote JE. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol. Epub 2005 Jun 27

  74. Serra DB, Affrime MG, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005; 45(9): 1038–47

    Article  PubMed  CAS  Google Scholar 

  75. Foote JE, Glavind K, Kay G. Central nervous system (CNS)-related adverse events in patients with overactive bladder (OAB) treated with darifenacin versus tolterodine [abstract]. BJU Int 2004; 94 Suppl. 2: 1134

    Google Scholar 

  76. Haab F. Darifenacin in the treatment of overactive bladder. Drugs Today (Barc) 2005 Jul; 41(7): 441–52

    Article  CAS  Google Scholar 

  77. European Medicines Agency (EMEA). Emselex European Public Assessment Report (EPAR): scientific discussion [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/emselex/emselex.htm [Accessed 2005 Feb 13]

  78. Kerbusch T, Milligan PA, Karlsson MO. Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br J Clin Pharmacol 2004; 57: 170–80

    Article  PubMed  CAS  Google Scholar 

  79. Study report A1371001. A phase 3, multicenter, double blind, randomized, placebo controlled, parallel group study of the efficacy and safety of controlled-release darifenacin versus tolterodine in the treatment of subjects with overactive bladder. East Hanover (NJ): Novartis, 2002 Aug 6. (Data on file)

  80. Romanzi LJ, Delconte III A, Kralidis G. Impact of darifenacin compared with tolterodine on incontinence episodes in patients with overactive bladder [abstract no. A3522]. Obstet Gynecol 2005; 105: 88S

    Google Scholar 

  81. Study report A1371002. A phase 3 multicentre, double blind, randomised, placebo controlled, dose response study of darifenacin in patients with overactive bladder (urge urinary incontinence). East Hanover (NJ): Novartis, 2002 Feb 18. (Data on file)

  82. Hill S, Khullar V, Wyndaele J-J, et al. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct. Epub 1995 Jul 6

  83. Study report A1371011. A phase 3, multicentre, double blind, randomised, placebo controlled, parallel group study of darifenacin versus tolterodine in patients with overactive bladder (urge urinary incontinence). East Hanover (NJ): Novartis, 2002 Apr 15. (Data on file)

  84. Study report A1371012. A phase 2 multicentre, placebo-controlled, double-blind, dose response study of controlled-release darifenacin in patients with overactive bladder (urinary urge incontinence). East Hanover (NJ): Novartis, 2002 Oct 25. (Data on file)

  85. Study report A1371013. A phase 3 multicentre, double blind, randomised, placebo controlled, parallel group study of darifenacin in patients with overactive bladder (urge urinary incontinence). East Hanover (NJ): Novartis, 2002 Apr 15. (Data on file)

  86. Study report A1371041. A phase 3b multicentre, double blind, randomised, placebo controlled, parallel group study of darifenacin in subjects with overactive bladder (urge urinary incontinence). East Hanover (NJ): Novartis, 2002 Nov 5. (Data on file)

  87. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated oncedaily treatment for overactive bladder. Eur Urol 2004; 45: 420–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The preparation of this manuscript was supported by Novartis Pharmaceuticals and editorial services were provided by ACUMED®. The author is an employee of Novartis Pharmaceuticals.

Author information

Authors and Affiliations

  1. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

    Andrej Skerjanec

Authors
  1. Andrej Skerjanec
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrej Skerjanec.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skerjanec, A. The Clinical Pharmacokinetics of Darifenacin. Clin Pharmacokinet 45, 325–350 (2006). https://doi.org/10.2165/00003088-200645040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200645040-00001

Keywords

Search

Navigation